The US Patent & Trademark Office (USPTO) has issued a notice of allowance for Elorac's patent application regarding novel acne therapy.
The US patent is entitled "Method and Composition for Treating Nodulocystic and Conglobate Acne Vulgaris."
Elorac intends to start a Phase II double-blind clinical trial of its once-weekly therapy in 2014.
According to the company, nodulocystic and conglobate acne are the most severe types of acne vulgaris affecting around 8-10 million patients in the US and causing substantial functional disability because of scarring.
Elorac president & CEO Jeffrey Bernstein said the product has several advantages over oral isotretinoin therapy, which has been the principal treatment for these types of severe disfiguring acne vulgaris.
"We are very pleased to receive the notice of allowance from the USPTO on this potential medical advance," Bernstein said.
US-based Elorac is involved in the development and commercialization of novel prescription products for dermatology and oncology.
